Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 128.00 | |
5 mg | In stock | $ 326.00 | |
10 mg | In stock | $ 490.00 | |
25 mg | In stock | $ 812.00 | |
50 mg | In stock | $ 1,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 443.00 |
Description | JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. |
In vitro | JND3229 potently inhibits the proliferation of BaF3 cells (harboring the EGFRL858R/T790M/C797S and EGFR19D/T790M/C797Smutations), NCI-H1975 NSCLC cells (with EGFRT790M mutation) and A431 cancer cells (overexpressing EGFRWT) with IC50 values of 0.51, 0.32, 0.31 and 0.27 µM, respectively. JND3229 (0.1, 0.3, 1, 3, 10 µM; 2 h) potently inhibits the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in engineering BaF3 cells[1]. |
In vivo | JND3229 (10 mg/kg; i.p.; twice daily for 10 days) exhibits an obvious suppression of tumor growth, and shows target inhibition in vivo[1]. |
Molecular Weight | 617.18 |
Formula | C33H41ClN8O2 |
CAS No. | 2260886-64-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11.7 mg/mL (19 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JND3229 2260886-64-2 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR JND-3229 JND 3229 inhibitor inhibit